Vaccine Therapy in Treating Patients With Malignant Melanoma

Status unconfirmed · Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating patients with malignant melanoma.

Key facts

Study ID

NCT00128583

Run by

CancerVax Corporation

Starts

2005-07-01

Last updated by the study team

2013-12-19

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Comprehensive Cancer Center at Desert Regional Medical Center — Palm Springs, California, United States
• John Wayne Cancer Institute at Saint John's Health Center — Santa Monica, California, United States
• Lakeland Regional Cancer Center at Lakeland Regional Medical Center — Lakeland, Florida, United States
• H. Lee Moffitt Cancer Center and Research Institute at University of South Florida — Tampa, Florida, United States
• CCOP - Dayton — Dayton, Ohio, United States
• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Simmons Cancer Center at University of Texas Southwestern Medical Center at Dallas — Dallas, Texas, United States
• M.D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
• LDS Hospital — Salt Lake City, Utah, United States
• Sydney Cancer Centre at Royal Prince Alfred Hospital — Sydney, New South Wales, Australia
• Princess Alexandra Hospital — Brisbane, Queensland, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.